Adaptive Biotechnologies Corp
ADPT14.380USD
+0.140+0.98%
收盘 10/03, 16:00（美东）报价延迟15分钟
2.19B总市值
亏损市盈率 TTM
关于 Adaptive Biotechnologies Corp 公司
Adaptive Biotechnologies Corporation 是一家商业阶段的生物技术公司。该公司专注于利用适应性免疫系统的固有生物学来改变疾病的诊断和治疗。其免疫医学平台应用其专有技术来读取患者免疫系统的多种遗传密码，并准确了解免疫系统如何检测和治疗该患者的疾病。该公司的业务主要围绕两个领域：淋巴恶性肿瘤中微小残留病 (MRD) 的临床评估和免疫医学 (IM) 驱动的药物发现和开发。MRD 业务专注于使用其高灵敏度的下一代测序 (NGS) 检测来测量血液系统恶性肿瘤患者的 MRD。该公司包括向临床医生提供的 clonoSEQ 临床诊断测试和向生物制药合作伙伴提供的 clonoSEQ 检测，以推进药物开发工作 (MRD Pharma)。
Adaptive Biotechnologies Corp简介
公司代码ADPT
公司名称Adaptive Biotechnologies Corp
上市日期Jun 27, 2019
CEOMr. Chad M. Robins
员工数量619
证券类型Ordinary Share
年结日Jun 27
公司地址1165 Eastlake Ave E
城市SEATTLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编98109
电话12066590067
网址https://www.adaptivebiotech.com
公司代码ADPT
上市日期Jun 27, 2019
CEOMr. Chad M. Robins
Adaptive Biotechnologies Corp公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
54.30K
+41.54%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-3.91%
Ms. Karina Calzadilla
Ms. Karina Calzadilla
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
收入明细
单位: USD更新时间: 10月2日 周四
单位: USD更新时间: 10月2日 周四
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
MRD revenue
49.94M
84.81%
Immune meidicine revenue
8.94M
15.19%
暂无数据
业务
地区
业务USD
名称
营收
占比
MRD revenue
49.94M
84.81%
Immune meidicine revenue
8.94M
15.19%
股东统计
更新时间: 9月22日 周一
更新时间: 9月22日 周一
持股股东
股东类型
持股股东
持股股东
占比
Viking Global Investors LP
19.70%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
7.27%
Rubric Capital Management LP
4.11%
Amova Asset Management Co., Ltd.
2.82%
其他
58.71%
持股股东
持股股东
占比
Viking Global Investors LP
19.70%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
7.27%
Rubric Capital Management LP
4.11%
Amova Asset Management Co., Ltd.
2.82%
其他
58.71%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
44.83%
Investment Advisor
35.68%
Hedge Fund
13.75%
Individual Investor
2.65%
Research Firm
2.02%
Venture Capital
0.96%
Bank and Trust
0.31%
Pension Fund
0.27%
Endowment Fund
0.14%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
480
149.40M
98.11%
-13.44M
2025Q2
498
148.68M
97.64%
-4.69M
2025Q1
498
156.30M
102.90%
-1.29M
2024Q4
481
143.31M
96.47%
-18.10M
2024Q3
478
143.38M
97.20%
-27.99M
2024Q2
486
149.83M
101.63%
-16.40M
2024Q1
506
146.67M
99.58%
-10.66M
2023Q4
529
145.23M
100.12%
-16.05M
2023Q3
531
142.64M
98.54%
-11.65M
2023Q2
545
137.84M
95.31%
-15.76M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Viking Global Investors LP
29.99M
19.7%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
11.26M
7.39%
+140.86K
+1.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.07M
7.27%
+1.28M
+13.03%
Jun 30, 2025
Rubric Capital Management LP
6.26M
4.11%
-6.86M
-52.30%
Jun 30, 2025
Amova Asset Management Co., Ltd.
4.30M
2.82%
-1.79M
-29.35%
Jun 30, 2025
ARK Investment Management LLC
4.02M
2.64%
-382.18K
-8.69%
Jun 30, 2025
Braidwell LP
3.86M
2.54%
-940.69K
-19.58%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.22M
2.11%
+434.35K
+15.62%
Jun 30, 2025
State Street Global Advisors (US)
3.03M
1.99%
+337.63K
+12.55%
Jun 30, 2025
Aristotle Atlantic Partners, LLC
2.88M
1.89%
-61.90K
-2.10%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
ARK Genomic Revolution ETF
4.12%
Franklin Genomic Advancements ETF
2.16%
ROBO Global Healthcare Technology & Innovation ETF
2.03%
Invesco Dorsey Wright Industrials Momentum ETF
1.44%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.79%
Even Herd Long Short ETF
0.75%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Invesco NASDAQ Future Gen 200 ETF
0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
iShares Micro-Cap ETF
0.41%
查看更多
ARK Genomic Revolution ETF
占比4.12%
Franklin Genomic Advancements ETF
占比2.16%
ROBO Global Healthcare Technology & Innovation ETF
占比2.03%
Invesco Dorsey Wright Industrials Momentum ETF
占比1.44%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比0.79%
Even Herd Long Short ETF
占比0.75%
First Trust Small Cap Growth AlphaDEX Fund
占比0.66%
Invesco NASDAQ Future Gen 200 ETF
占比0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.51%
iShares Micro-Cap ETF
占比0.41%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
